MiniMed Group, Inc. Common Stock (MMED) Stock Score, Valuation & Financial Research
MiniMed Group, Inc. Common Stock is in the Healthcare sector and Medical - Equipment & Services industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 33/100.
Quick answer for MMED
MiniMed Group, Inc. Common Stock currently has a Wall Street Score of 33/100. The stored market price is $22.5. Its financial score is 42/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What MiniMed Group, Inc. Common Stock does
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories. These innovations are crafted to enable both patients and healthcare providers to accurately monitor and precisely regulate blood glucose levels. The enterprise was established in 1983 by Alfred E. Mann and is currently headquartered in Northridge, California.
MMED financial snapshot
- Wall Street Score:
- 33/100
- Current price:
- $22.5
- Market capitalization:
- $6.32B
- Revenue:
- $3.10B
- Net income:
- $-331.0M
- Free cash flow:
- $-420.0M
- Cash:
- $298.0M
- Total debt:
- $145.0M
- EPS:
- -1.29
- Financial score:
- 42/100
- Valuation score:
- 0/100
- Revenue score:
- 31/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-420.0M, showing cash burn in the current stored period.
- The balance sheet shows $298.0M of cash versus $145.0M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 42/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research MMED
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.